In november 2017, ORPHY obtained the funding of the Hemlyo Project. Hemlyo is led by Hemarina (a novative company in Biotechnology) in association with Lyofal Company and ORPHY. It is funded by the European Union, Britany, Finistère and the city of Morlaix. It has been labeled by “Pôle mer” and “Atlanpole Biotherapies”. Its aim is to develop the first universal oxygen transporter - in its lyophilized form - obtained from marine worms. This technology would allow innovation in terms of oxygenation in health biology, thereby filling in for the absence of a similar product on the market.